MS Connect
  • Saved

1yr
Diagnostic and Prognostic Innovations in MS

In this video highlighting key takeaways from ECTRIMS 2024, Dr. David A. Hafler, Chairman of the Department of Neurology and Professor of Immunology at Yale School of Medicine, presented advancements in the diagnosis and treatment of Multiple Sclerosis (MS), focusing on genetic biomarkers that predict disease progression. He emphasized the potential of Bruton's Tyrosine Kinase (BTK) inhibitors for treating relapsing-remitting MS, particularly in patients with autoimmune conditions, and discussed the connection between genetic variants and disease progression in the brain and central nervous system. Dr. Hafler also highlighted B-cell suppression as a promising first-line treatment, with evidence supporting the role of the Epstein-Barr virus in triggering immune responses that affect B cells.

  • Saved

1yr
Unleashing the power of anti-CD20 immunotherapy: Mitigating multiple sclerosis risk in Epstein-Barr virus latent infections - PubMed

Unleashing the power of anti-CD20 immunotherapy: Mitigating multiple sclerosis risk in Epstein-Barr virus latent infections - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38085006/

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative connective tissue disease affecting the central nervous system (CNS). Recently, there has been a dramatic improvement in several vital concepts...

Anti-CD20 monoclonal antibodies show promise in treating multiple sclerosis by targeting EBV-associated memory B cells, despite potential adverse effects that can be managed with careful planning.

  • Saved

1yr
Dermatological Neoplastic Diseases Complicating Treatment with Monoclonal Antibodies for Multiple Sclerosis - PubMed

Dermatological Neoplastic Diseases Complicating Treatment with Monoclonal Antibodies for Multiple Sclerosis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39274345/

Background: Over the past 20 years, the treatment scenario of multiple sclerosis (MS) has radically changed, and an ever-increasing number of disease-modifying treatments has emerged. Among high-efficacy treatment agents, monoclonal...

This review examines cutaneous malignancies in multiple sclerosis patients receiving monoclonal antibodies, assessing the need for dermatological follow-ups due to unclear cancer risk associations.

  • Saved

1yr
What's new in NMOSD and MOGAD? - PubMed

What's new in NMOSD and MOGAD? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39277477/

In this mini-review, we focus on novelties in the field of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD). We first describe the proposed criteria...

This review explores recent advancements in NMOSD and MOGAD, focusing on diagnostic criteria, clinical features of double seronegative cases, and future treatment.

  • Saved

1yr
Targeting ferroptosis in neuroimmune and neurodegenerative disorders for the development of novel therapeutics - PubMed

Targeting ferroptosis in neuroimmune and neurodegenerative disorders for the development of novel therapeutics - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38795640/

Neuroimmune and neurodegenerative ailments impose a substantial societal burden. Neuroimmune disorders involve the intricate regulatory interactions between the immune system and the central nervous system. Prominent examples of neuroimmune disorders...

Ferroptosis, characterized by lipid peroxidation and iron overload, affects neuroimmune and neurodegenerative diseases. This review covers its mechanisms, impacts on immune and neural cells, and therapeutic potential.